A longitudinal study highlights shared aspects of the transcriptomic response to cardiogenic and septic shock

Daniele Braga, Matteo Barcella, Antoine Herpain, Federico Aletti, Erik B Kistler, Bernardo Bollen Pinto, Karim Bendjelid, Cristina Barlassina, Daniele Braga, Matteo Barcella, Antoine Herpain, Federico Aletti, Erik B Kistler, Bernardo Bollen Pinto, Karim Bendjelid, Cristina Barlassina

Abstract

Background: Septic shock (SS) and cardiogenic shock (CS) are two types of circulatory shock with a different etiology. Several studies have described the molecular alterations in SS patients, whereas the molecular factors involved in CS have been poorly investigated. We aimed to assess in the whole blood of CS and SS patients, using septic patients without shock (SC) as controls, transcriptomic modifications that occur over 1 week after ICU admission and are common to the two types of shock.

Methods: We performed whole blood RNA sequencing in 21 SS, 11 CS, and 5 SC. In shock patients, blood samples were collected within 16 h from ICU admission (T1), 48 h after ICU admission (T2), and at day 7 or before discharge (T3). In controls, blood samples were available at T1 and T2. Gene expression changes over time have been studied in CS, SS, and SC separately with a paired analysis. Genes with p value < 0.01 (Benjamini-Hochberg multiple test correction) were defined differentially expressed (DEGs). We used gene set enrichment analysis (GSEA) to identify the biological processes and transcriptional regulators significantly enriched in both types of shock.

Results: In both CS and SS patients, GO terms of inflammatory response and pattern recognition receptors (PRRs) were downregulated following ICU admission, whereas gene sets of DNA replication were upregulated. At the gene level, we observed that alarmins, interleukin receptors, PRRs, inflammasome, and DNA replication genes significantly changed their expression in CS and SS, but not in SC. Analysis of transcription factor targets showed in both CS and SS patients, an enrichment of CCAAT-enhancer-binding protein beta (CEBPB) targets in genes downregulated over time and an enrichment of E2F targets in genes with an increasing expression trend.

Conclusions: This pilot study supports, within the limits of a small sample size, the role of alarmins, PRRs, DNA replication, and immunoglobulins in the pathophysiology of circulatory shock, either in the presence of infection or not. We hypothesize that these genes could be potential targets of therapeutic interventions in CS and SS.

Trial registration: ClinicalTrials.gov, NCT02141607. Registered 19 May 2014.

Keywords: Cardiogenic shock; Circulatory shock; Critical illness; Immunoglobulin; PRR; RNA-Seq; Septic shock.

Conflict of interest statement

The authors declare that they have no competing interests.

Figures

Fig. 1
Fig. 1
PCA plot of CS and SS patients. PCA plot of CS patients at three time points (a). PCA plot of SS patients at three time points (b). PCA plot of SC patients at T1 and T2 (c). PCs were adjusted in order to remove the patient effect
Fig. 2
Fig. 2
Inflammatory pathway, pattern recognition receptors, and DNA replication. Expression trends of significantly modulated genes in CS and SS, but not in SC patients. Data are normalized on T1; log2FoldChanges are plotted
Fig. 3
Fig. 3
Gene expression trends of enriched transcription factor targets in CS and SS. CEBPB and E2F target genes are shown. Data are normalized on T1; log2FoldChanges are plotted
Fig. 4
Fig. 4
Boxplots of C-reactive protein serum measurements. C-reactive protein measurements (mg/L) in cardiogenic and septic shock patients measured at three time points. The lower and upper hinges correspond to the 25th and 75th percentiles, respectively

References

    1. Vincent J-L, De Backer D. Circulatory shock. N Engl J Med. 2013;369:1726–1734. doi: 10.1056/NEJMra1208943.
    1. Cecconi M, De Backer D, Antonelli M, Beale R, Bakker J, Hofer C, et al. Consensus on circulatory shock and hemodynamic monitoring. Task Force of the European Society of Intensive Care Medicine. Intensive Care Med. 2014;40:1795–1815. doi: 10.1007/s00134-014-3525-z.
    1. Daviaud F, Grimaldi D, Dechartres A, Charpentier J, Geri G, Marin N, et al. Timing and causes of death in septic shock. Ann Intensive Care. 2015;5:16. doi: 10.1186/s13613-015-0058-8.
    1. Shankar-Hari M, Phillips GS, Levy ML, Seymour CW, Liu VX, Deutschman CS, et al. Developing a new definition and assessing new clinical criteria for septic shock. JAMA. 2016;315:775–787. doi: 10.1001/jama.2016.0289.
    1. Cecconi M, Evans L, Levy M, Rhodes A. Sepsis and septic shock. Lancet. 2018;392:75–87. doi: 10.1016/S0140-6736(18)30696-2.
    1. Van Diepen S, Katz JN, Albert NM, Henry TD, Jacobs AK, Kapur NK, et al. Contemporary management of cardiogenic shock: a scientific statement from the American Heart Association. Circulation. 2017;136:e232–e268. doi: 10.1161/CIRCULATIONAHA.117.029532.
    1. Cazalis M-A, Lepape A, Venet F, Frager F, Mougin B, Vallin H, et al. Early and dynamic changes in gene expression in septic shock patients: a genome-wide approach. Intensive Care Med Exp. 2014;2:20. doi: 10.1186/s40635-014-0020-3.
    1. Almansa R, Heredia-Rodriguez M, Gomez-Sanchez E, Andaluz-Ojeda D, Iglesias V, Rico L, et al. Transcriptomic correlates of organ failure extent in sepsis. J Inf Secur. 2015;70:445–456.
    1. Burnham KL, Davenport EE, Radhakrishnan J, Humburg P, Gordon AC, Hutton P, et al. Shared and distinct aspects of the sepsis transcriptomic response to fecal peritonitis and pneumonia. Am J Respir Crit Care Med. 2017;196:328–339. doi: 10.1164/rccm.201608-1685OC.
    1. Kalenka A, Feldmann RE, Otero K, Maurer MH, Waschke KF, Fiedler F. Changes in the serum proteome of patients with sepsis and septic shock. Anesth Analg. 2006;103:1522–1526. doi: 10.1213/01.ane.0000242533.59457.70.
    1. Cambiaghi A, Pinto BB, Brunelli L, Falcetta F, Aletti F, Bendjelid K, et al. Characterization of a metabolomic profile associated with responsiveness to therapy in the acute phase of septic shock. Sci Rep. 2017;7:9748. doi: 10.1038/s41598-017-09619-x.
    1. Cambiaghi A, Díaz R, Martinez JB, Odena A, Brunelli L, Caironi P, et al. An innovative approach for the integration of proteomics and metabolomics data in severe septic shock patients stratified for mortality. Sci Rep. 2018;8:6681. doi: 10.1038/s41598-018-25035-1.
    1. Beloborodova NV, Olenin AY, Pautova AK. Metabolomic findings in sepsis as a damage of host-microbial metabolism integration. J Crit Care. 2018;43:246–255. doi: 10.1016/j.jcrc.2017.09.014.
    1. Bauzá-Martinez J, Aletti F, Pinto BB, Ribas V, Odena MA, Díaz R, et al. Proteolysis in septic shock patients: plasma peptidomic patterns are associated with mortality. Br J Anaesth. 2018;121:1065–1074. doi: 10.1016/j.bja.2018.05.072.
    1. Aletti F, Conti C, Ferrario M, Ribas V, Bollen Pinto B, Herpain A, et al. ShockOmics: multiscale approach to the identification of molecular biomarkers in acute heart failure induced by shock. Scand J Trauma Resusc Emerg Med. 2016;24:9. doi: 10.1186/s13049-016-0197-4.
    1. Dobin A, Davis CA, Schlesinger F, Drenkow J, Zaleski C, Jha S, et al. STAR: ultrafast universal RNA-seq aligner. Bioinformatics. 2013;29:15–21. doi: 10.1093/bioinformatics/bts635.
    1. Liao Y, Smyth GK, Shi W. FeatureCounts: an efficient general purpose program for assigning sequence reads to genomic features. Bioinformatics. 2014;30:923–930. doi: 10.1093/bioinformatics/btt656.
    1. Love MI, Huber W, Anders S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 2014;15:550. doi: 10.1186/s13059-014-0550-8.
    1. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci. 2005;102:15545–15550. doi: 10.1073/pnas.0506580102.
    1. Parenica J, Jarkovsky J, Malaska J, Mebazaa A, Gottwaldova J, Helanova K, et al. Infectious complications and immune/inflammatory response in cardiogenic shock patients: a prospective observational study. Shock. 2017;47:165–174. doi: 10.1097/SHK.0000000000000756.
    1. Dolinay T, Kim YS, Howrylak J, Hunninghake GM, An CH, Fredenburgh L, et al. Inflammasome-regulated cytokines are critical mediators of acute lung injury. Am J Respir Crit Care Med. 2012;185:1225–1234. doi: 10.1164/rccm.201201-0003OC.
    1. Wiersinga WJ, Leopold SJ, Cranendonk DR, van der Poll T. Host innate immune responses to sepsis. Virulence. 2014;5:36–44. doi: 10.4161/viru.25436.
    1. Kawai T, Akira S. The role of pattern-recognition receptors in innate immunity: update on toll-like receptors. Nat Immunol. 2010;11:373–384. doi: 10.1038/ni.1863.
    1. Tsujimoto H, Ono S, Efron PA, Scumpia PO, Moldawer LL, Mochizuki H. Role of Toll-like receptors in the development of sepsis. Shock. 2008;29:315–321.
    1. West XZ, Malinin NL, Merkulova AA, Tischenko M, Kerr BA, Borden EC, et al. Oxidative stress induces angiogenesis by activating TLR2 with novel endogenous ligands. Nature. 2010;467:972–976. doi: 10.1038/nature09421.
    1. Kadl A, Sharma PR, Chen W, Agrawal R, Meher AK, Rudraiah S, et al. Oxidized phospholipid-induced inflammation is mediated by Toll-like receptor 2. Free Radic Biol Med. 2011;51:1903–1909. doi: 10.1016/j.freeradbiomed.2011.08.026.
    1. Richardson MB, Williams SJ. MCL and Mincle: C-type lectin receptors that sense damaged self and pathogen-associated molecular patterns. Front Immunol. 2014;5:1–9. doi: 10.3389/fimmu.2014.00288.
    1. Kakihana Y, Ito T, Nakahara M, Yamaguchi K, Yasuda T. Sepsis-induced myocardial dysfunction; pathophysiology and management. J Intensive Care. 2016;4:22. doi: 10.1186/s40560-016-0148-1.
    1. Rudiger A. Understanding cardiogenic shock. Eur J Heart Fail. 2015;17:466–467. doi: 10.1002/ejhf.265.
    1. Yu Lili, Feng Zhiwei. The Role of Toll-Like Receptor Signaling in the Progression of Heart Failure. Mediators of Inflammation. 2018;2018:1–11.
    1. Hochman JS. Cardiogenic shock complicating acute myocardial infarction: expanding the paradigm. Circulation. 2003;107:2998–3002. doi: 10.1161/01.CIR.0000075927.67673.F2.
    1. Lawler PR, Mehra MR. Advancing from a “hemodynamic model” to a “mechanistic disease-modifying model” of cardiogenic shock. J Hear Lung Transplant. 2018;37:1285–1288. doi: 10.1016/j.healun.2018.07.009.
    1. Xiang M, Fan J. Pattern recognition receptor-dependent mechanisms of acute lung injury. Mol Med. 2010;16:69–82. doi: 10.2119/molmed.2009.00097.
    1. Huber R, Pietsch D, Panterodt T, Brand K. Regulation of C/EBPβ and resulting functions in cells of the monocytic lineage. Cell Signal. 2012;24:1287–1296. doi: 10.1016/j.cellsig.2012.02.007.
    1. Taccone FS, Stordeur P, De Backer D, Creteur J, Vincent JL. γ-Globulin levels in patients with community-acquired septic shock. Shock. 2009;32:379–385. doi: 10.1097/SHK.0b013e3181a2c0b2.
    1. Tamayo E, Fernández A, Almansa R, Carrasco E, Goncalves L, Heredia M, et al. Beneficial role of endogenous immunoglobulin subclasses and isotypes in septic shock. J Crit Care. 2012;27:616–622. doi: 10.1016/j.jcrc.2012.08.004.
    1. Andaluz-Ojeda D, Iglesias V, Bobillo F, Almansa R, Rico L, Gandía F, et al. Early natural killer cell counts in blood predict mortality in severe sepsis. Crit Care. 2011;15:R243. doi: 10.1186/cc10501.
    1. Venet F, Gebeile R, Bancel J, Guignant C, Poitevin-Later F, Malcus C, et al. Assessment of plasmatic immunoglobulin G, a and M levels in septic shock patients. Int Immunopharmacol. 2011;11:2086–2090. doi: 10.1016/j.intimp.2011.08.024.
    1. Andaluz-Ojeda D, Iglesias V, Bobillo F, Nocito M, Loma AM, Nieto C, et al. Early levels in blood of immunoglobulin M and natural killer cells predict outcome in nonseptic critically ill patients. J Crit Care. 2013;28:1110. doi: 10.1016/j.jcrc.2013.06.007.
    1. Binder CJ. Natural IgM antibodies against oxidation-specific epitopes. J Clin Immunol. 2010;30:S56–S60. doi: 10.1007/s10875-010-9396-3.
    1. Bermejo-Martin JF, Giamarellos-Bourboulis EJ. Endogenous immunoglobulins and sepsis: new perspectives for guiding replacement therapies. Int J Antimicrob Agents. 2015;46:S25–S28. doi: 10.1016/j.ijantimicag.2015.10.013.
    1. Ren B, Cam H, Takahashi Y, Volkert T, Terragni J, Young RA, et al. E2F integrates cell cycle progression with DNA repair, replication, and G2/M checkpoints. Genes Dev. 2002;16:245–256. doi: 10.1101/gad.949802.
    1. Helin K. Regulation of cell proliferation by the E2F transcription factors. Curr Opin Genet Dev. 1998;8:28–35. doi: 10.1016/S0959-437X(98)80058-0.
    1. Hotchkiss RS, Monneret G, Payen D. Sepsis-induced immunosuppression: from cellular dysfunctions to immunotherapy. Nat Rev Immunol. 2013;13:862–874. doi: 10.1038/nri3552.
    1. Lewis AJ, Billiar TR, Rosengart MR. Biology and metabolism of sepsis: innate immunity, bioenergetics, and autophagy. Surg Infect. 2016;17:286–293. doi: 10.1089/sur.2015.262.
    1. Dewitte A, Lepreux S, Villeneuve J, Rigothier C, Combe C, Ouattara A, et al. Correction to: Blood platelets and sepsis pathophysiology: a new therapeutic prospect in critically ill patients? Ann Intensive Care. 2018;8:32. doi: 10.1186/s13613-018-0378-6.
    1. Davenport EE, Burnham KL, Radhakrishnan J, Humburg P, Hutton P, Mills TC, et al. Genomic landscape of the individual host response and outcomes in sepsis: a prospective cohort study. Lancet Respir Med. 2016;4:259–271. doi: 10.1016/S2213-2600(16)00046-1.
    1. Marshall JC. Why have clinical trials in sepsis failed? Trends Mol Med. 2014;20:195–203. doi: 10.1016/j.molmed.2014.01.007.
    1. Harjola VP, Mebazaa A, Čelutkiene J, Bettex D, Bueno H, Chioncel O, et al. Contemporary management of acute right ventricular failure: a statement from the Heart Failure Association and the Working Group on Pulmonary Circulation and Right Ventricular Function of the European Society of Cardiology. Eur J Heart Fail. 2016;18:226–241. doi: 10.1002/ejhf.478.
    1. Lawler PR, Fan E. Heterogeneity and phenotypic stratification in acute respiratory distress syndrome. Lancet Respir Med. 2018;6:651–653. doi: 10.1016/S2213-2600(18)30287-X.
    1. Hyman DM, Puzanov I, Subbiah V, Faris JE, Chau I, Blay JY, et al. Vemurafenib in multiple nonmelanoma cancers with BRAF V600 mutations. N Engl J Med. 2015;373:726–736. doi: 10.1056/NEJMoa1502309.

Source: PubMed

스폰서 및 공동 작업자

건강 상태

약물 개입

3
구독하다